Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclarion, Inc. stock logo
ACON
Aclarion
$6.94
+0.6%
$11.16
$6.20
$3,499.51
$4.04M1.1356,607 shs12,332 shs
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
$1.61
-3.6%
$1.76
$1.03
$2.55
$12.08M77.73543,037 shs31,661 shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.36
$0.25
$1.28
$17.03M1.19166,686 shs4.12 million shs
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$1.47
+6.5%
$2.31
$1.32
$16.80
$7.60M2.45280,060 shs98,777 shs
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclarion, Inc. stock logo
ACON
Aclarion
0.00%-2.25%-22.72%-94.29%-99.72%
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
0.00%-10.56%-8.00%-29.69%+17.52%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%+0.62%-39.81%-70.45%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.00%-16.24%-42.80%-69.63%-97.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aclarion, Inc. stock logo
ACON
Aclarion
1.2517 of 5 stars
3.32.00.00.00.90.00.6
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
3.4534 of 5 stars
3.55.00.00.01.03.31.3
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.2819 of 5 stars
0.02.00.00.01.71.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclarion, Inc. stock logo
ACON
Aclarion
2.50
Moderate Buy$11,758.50169,330.84% Upside
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
3.00
Buy$18.001,018.01% Upside
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclarion, Inc. stock logo
ACON
Aclarion
$45.72K88.34N/AN/A($125.39) per share-0.06
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
$401K30.13N/AN/A$2.45 per share0.66
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$615.87K12.34N/AN/A$0.54 per share2.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclarion, Inc. stock logo
ACON
Aclarion
-$4.91MN/A0.00N/AN/A-12,845.05%-422.87%-201.15%5/21/2025 (Estimated)
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$14.41M-$1.16N/AN/AN/A-2,697.08%-98.49%-75.23%N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%6/12/2025 (Estimated)
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
-$9.21M-$4.85N/AN/A-1,237.00%-138.00%-118.88%5/21/2025 (Estimated)

Latest ACON, ENZ, BRTX, and MGRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Aclarion, Inc. stock logo
ACON
Aclarion
N/A-$9.32N/A-$9.32N/AN/A
5/15/2025Q1 2025
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A-$1.29N/A-$1.29N/A$0.11 million
5/14/2025Q1 2025
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 million
3/27/2025Q4 2024
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$0.27-$0.20+$0.07-$0.20$0.48 million$0.50 million
3/20/2025Q4 2024
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A-$1.01N/A-$1.01N/A$0.11 million
3/17/2025Q2 2025
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A-$0.02N/A-$0.03N/A$7.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aclarion, Inc. stock logo
ACON
Aclarion
N/AN/AN/AN/AN/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclarion, Inc. stock logo
ACON
Aclarion
N/A
2.80
2.80
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/A
2.95
2.95
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A
0.07
0.07

Institutional Ownership

CompanyInstitutional Ownership
Aclarion, Inc. stock logo
ACON
Aclarion
7.52%
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
69.38%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
56.72%

Insider Ownership

CompanyInsider Ownership
Aclarion, Inc. stock logo
ACON
Aclarion
0.77%
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
25.50%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclarion, Inc. stock logo
ACON
Aclarion
7582,000505,000Not Optionable
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
77.51 million5.16 millionNot Optionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
35.17 million1.51 millionNot Optionable

Recent News About These Companies

Mangoceuticals launches PeachesRx women’s telehealth brand

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aclarion stock logo

Aclarion NASDAQ:ACON

$6.94 +0.04 (+0.58%)
Closing price 05/16/2025 04:00 PM Eastern
Extended Trading
$6.80 -0.14 (-2.02%)
As of 05/16/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

BioRestorative Therapies stock logo

BioRestorative Therapies NASDAQ:BRTX

$1.61 -0.06 (-3.59%)
Closing price 05/16/2025 04:00 PM Eastern
Extended Trading
$1.66 +0.04 (+2.80%)
As of 05/16/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Mangoceuticals stock logo

Mangoceuticals NASDAQ:MGRX

$1.47 +0.09 (+6.52%)
Closing price 05/16/2025 04:00 PM Eastern
Extended Trading
$1.44 -0.03 (-2.04%)
As of 05/16/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.